Topline results from the Synuclein-One Study, presented at the American Academy of Neurology Annual Meeting in Boston April 22-27, were covered by several news outlets over the past two weeks. In the study, the Syn-One Test® demonstrated higher sensitivity and specificity than any alpha-synuclein biomarker test to date. The Synuclein-One Study also highlighted the safety and convenience of using skin biopsies to detect alpha-synuclein.
A write-up of the study appeared on NeurologyLive along with an interview with CND Life Sciences’ Chief Medical Officer and Co-Founder, Dr. Todd Levine, about the role of the Syn-One Test in diagnosing neurodegenerative disorders. Additional coverage about the test’s high sensitivity rate and clinical impact appeared in MedicalDevice Network and Parkinson’s News Today.